UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  December 24, 2004

 

EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

1-15525

 

36-4316614

(State or other jurisdiction
of incorporation)

 

(Commission
file number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

One Edwards Way, Irvine, California

 

92614

(Address of principal executive offices)

 

(Zip Code)

 

(949) 250-2500

Registrant’s telephone number, including area code

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                                    Pre-Commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

Item 1.01.                                          Entry into a Material Definitive Agreement.

 

On December 24, 2004, the Compensation and Governance Committee of the Board of Directors of Edwards Lifesciences Corporation (the “Company”) adopted the Edwards Lifesciences Corporation Executive Deferred Compensation Plan, effective as of January 1, 2005 (the “Plan”).  It is expected that one or more of the Company’s executive officers will participate in the Plan.

 

In summary, the Plan provides selected employees with the opportunity to defer specified percentages of their cash compensation and receive matching employer contributions that could not be deferred or contributed to the Edwards Lifesciences Corporation 401(k) Savings and Investment Plan because of the limitations under such plan.  The Plan also permits the participants to defer up to 100% of their base pay and annual incentive bonus.  Participants may elect distributions of deferred compensation to be paid in a lump sum or in installments upon separation from service, death or a specified date.  Deferrals are credited with gain or loss based on the performance of one or more investment options selected by the participant from various investment funds.  No actual investments will be held in the participant’s accounts and participants remain general unsecured creditors of the Company with respect to their account balances.  Although the Compensation and Governance Committee has discretion to amend, suspend or terminate the Plan, it may not reduce amounts credited to a participant’s account.

 

A copy of the Plan is attached as exhibit 10.1.

 

Item 9.01.

 

Financial Statements and Exhibits.

 

 

 

(c)  

 

Exhibits

 

 

 

10.1

 

Edwards Lifesciences Corporation Executive Deferred Compensation Plan.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: December 24, 2004

 

 

 

EDWARDS LIFESCIENCES CORPORATION

 

 

 

 

 

 

 

By:

/s/ Bruce P. Garren

 

 

Bruce P. Garren

 

Corporate Vice President, General Counsel

 

3



 

Exhibit Index

 

Exhibit
Number

 

Description

 

 

 

10.1

 

Edwards Lifesciences Corporation Executive Deferred Compensation Plan.

 

4